We’re very proud to announce that Symbiosis is working with Modus Therapeutics Holding AB, a company developing innovative treatments for patients with high unmet medical needs, to manufacture their sevuparin drug product, securing the supply for the Phase II clinical development in sepsis/septic shock and other conditions driven by systemic inflammation.
Click here to find out more about this partnership: https://www.modustx.com/press-release?releaseIdentifier=F1DBF85B7C62D6DC
